Lung function at 1-year follow-up in patients with persistent dyspnea after mild COVID-19 – comparisons with moderate and critical COVID-19
Abstract
Aim: To assess lung function in patients with persistent dyspnea 1 year after mild coronavirus disease 2019 (COVID-19) and compare with those hospitalized with moderate or critical COVID-19.
Methods: Adults with confirmed severe acute respiratory syndrome coronavirus-2 infection with mild COVID-19 and persistent dyspnea (n = 18) or with moderate (n = 34) or critical COVID-19 (n = 19) were followed up 11–13 months after initial infection. Inclusion criteria were age < 65 years, no smoking history, and no preexisting respiratory diseases. Sociodemographic and clinical data were collected, and patients underwent spirometry and measurement of diffusing capacity for carbon monoxide (DLCO).
Results: The non-hospitalized patients were significantly younger and more often female compared with those in the moderate and critical groups (P = 0.002 and P < 0.001, respectively). No significant differences in comorbidities or body mass index (BMI) were noted between severity groups. An obstructive spirometry pattern (ratio of forced expiratory volume during the first exhalation second to forced vital capacity under the lower limit of normal (LLN)) was found in 5.6, 5.9, and 5.3% of patients in the mild, moderate, and critical groups, respectively (P = 0.995). Abnormal DLCO (< LLN) rates were seen in 5.6, 16.7, and 47.4% in the mild, moderate, and critical groups, respectively (P = 0.018). DLCO, expressed as a z-score, was significantly lower in the critical group compared with the mild group after adjustment for age, sex, and BMI.
Conclusion: Only a few subjects with mild COVID-19 and persistent dyspnea had abnormal lung function 1 year after initial infection, assessed based on spirometry and DLCO measurements. An obstructive spirometry pattern at 1-year follow-up was uncommon even in patients with moderate or critical COVID-19. Impaired DLCO was more common in patients with critical COVID-19.
Downloads
References
2. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7. doi: 10.1016/S1473-3099(21)00703-9
3. Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28(1):423–33. doi: 10.1038/s41380-022-01614-7
4. Lee JH, Yim JJ, Park J. Pulmonary function and chest computed tomography abnormalities 6–12 months after recovery from COVID-19: a systematic review and meta-analysis. Respir Res. 2022;23(1):233. doi: 10.1186/s12931-022-02163-x
5. Zhi H, Ji X, Zhao Z, Liang H, Zhong S, Luo Y, et al. Risk factors for impaired pulmonary diffusion function in convalescent COVID-19 patients: a systematic review and meta-analysis. EClinicalMedicine. 2022;49:101473. doi: 10.1016/j.eclinm.2022.101473
6. Bjorsell T, Sundh J, Lange A, Ahlm C, Forsell MNE, Tevell S, et al. Risk factors for impaired respiratory function post COVID-19: a prospective cohort study of nonhospitalized and hospitalized patients. J Intern Med. 2023;293(5):600–14. doi: 10.1111/joim.13614
7. Steinbeis F, Thibeault C, Doellinger F, Ring RM, Mittermaier M, Ruwwe-Glosenkamp C, et al. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: an observational longitudinal study over 12 months. Respir Med. 2022;191:106709. doi: 10.1016/j.rmed.2021.106709
8. Johnsen S, Sattler SM, Miskowiak KW, Kunalan K, Victor A, Pedersen L, et al. Descriptive analysis of long COVID sequelae identified in a multidisciplinary clinic serving hospitalised and non-hospitalised patients. ERJ Open Res. 2021;7(3):00205–2021. doi: 10.1183/23120541.00205-2021
9. Dotan R. Functional threshold power and the critical-power controversy. J Sports Sci. 2023;41(9):910–11. doi: 10.1080/02640414.2023.2245993
10. Taverne J, Salvator H, Leboulch C, Barizien N, Ballester M, Imhaus E, et al. High incidence of hyperventilation syndrome after COVID-19. J Thorac Dis. 2021;13(6):3918–22. doi: 10.21037/jtd-20-2753
11. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–71. doi: 10.1016/j.jacc.2020.03.031
12. Wen Y, Wang D, Zhou M, Zhou Y, Guo Y, Chen W. Potential effects of lung function reduction on health-related quality of life. Int J Environ Res Public Health. 2019;16(2):260. doi: 10.3390/ijerph16020260
13. Duong M, Usman A, Ma J, Xie Y, Huang J, Zaman M, et al. Associations between lung function and physical and cognitive health in the Canadian Longitudinal Study on Aging (CLSA): a cross-sectional study from a multicenter national cohort. PLoS Med. 2022;19(2):e1003909. doi: 10.1371/journal.pmed.1003909
14. Kisiel MA, Nordqvist T, Westman G, Svartengren M, Malinovschi A, Janols H. Patterns and predictors of sick leave among Swedish non-hospitalized healthcare and residential care workers with COVID-19 during the early phase of the pandemic. PLoS One. 2021;16(12):e0260652. doi: 10.1371/journal.pone.0260652
15. Kisiel MA, Janols H, Nordqvist T, Bergquist J, Hagfeldt S, Malinovschi A, et al. Predictors of post-COVID-19 and the impact of persistent symptoms in non-hospitalized patients 12 months after COVID-19, with a focus on work ability. Ups J Med Sci. 2022;127:8794. doi: 10.48101/ujms.v127.8794
16. Kisiel MA, Lee S, Malmquist S, Rykatkin O, Holgert S, Janols H, et al. Clustering analysis identified three long COVID phenotypes and their association with general health status and working ability. J Clin Med. 2023;12(11):3617. doi: 10.3390/jcm12113617
17. Ekbom E FR, Emilsson Öi, Larson IM, Lipcsey M, Rubertsson S, Wallin E, et al. Impaired diffusing capacity for carbon monoxide is common in critically ill Covid-19 patients at four months post-discharge. Respir Med. 2021;182:106394. doi: 10.1016/j.rmed.2021.106394
18. Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. doi: 10.1183/13993003.01499-2021
19. Stanojevic S. Standardisation of lung function test interpretation: global lung function initiative. Lancet Respir Med. 2018;6(1):10–12. doi: 10.1016/S2213-2600(17)30472-1
20. WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–7.
21. Watanabe A, So M, Iwagami M, Fukunaga K, Takagi H, Kabata H, et al. One-year follow-up CT findings in COVID-19 patients: a systematic review and meta-analysis. Respirology. 2022;27(8):605–16. doi: 10.1111/resp.14311
22. van Voorthuizen EL, van Helvoort HAC, Peters JB, van den Heuvel MM, van den Borst B. Persistent exertional dyspnea and perceived exercise intolerance after mild COVID-19: a critical role for breathing dysregulation? Phys Ther. 2022;102(10):pzac105. doi: 10.1093/ptj/pzac105
23. Ye L, Yao G, Lin S, Fang Y, Chen X, Wang L, et al. The investigation of pulmonary function changes of COVID-19 patients in three months. J Healthc Eng. 2022;2022:9028835. doi: 10.1155/2022/9028835
24. van Willigen HDG, Wynberg E, Verveen A, Dijkstra M, Verkaik BJ, Figaroa OJA, et al. One-fourth of COVID-19 patients have an impaired pulmonary function after 12 months of disease onset. PLoS One. 2023;18(9):e0290893. doi: 10.1371/journal.pone.0290893
25. Lang M, Som A, Mendoza DP, Flores EJ, Reid N, Carey D, et al. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. Lancet Infect Dis. 2020;20(12):1365–6. doi: 10.1016/S1473-3099(20)30367-4
26. Hanidziar D, Robson SC. Hyperoxia and modulation of pulmonary vascular and immune responses in COVID-19. Am J Physiol Lung Cell Mol Physiol. 2021;320(1):L12–16. doi: 10.1152/ajplung.00304.2020
27. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. doi: 10.1183/13993003.00607-2020
28. Neff TA, Stocker R, Frey HR, Stein S, Russi EW. Long-term assessment of lung function in survivors of severe ARDS. Chest. 2003;123(3):845–53. doi: 10.1378/chest.123.3.845
29. Ramirez-Soto MC, Ortega-Caceres G, Arroyo-Hernandez H. Sex differences in COVID-19 fatality rate and risk of death: an analysis in 73 countries, 2020–2021. Infez Med. 2021;29(3):402–7. doi: 10.53854/liim-2903-11
30. Ni Y, Yu Y, Dai R, Shi G. Diffusing capacity in chronic obstructive pulmonary disease assessment: a meta-analysis. Chron Respir Dis. 2021;18:14799731211056340. doi: 10.1177/14799731211056340
31. Uruma Y, Manabe T, Fujikura Y, Iikura M, Hojo M, Kudo K. Effect of asthma, COPD, and ACO on COVID-19: a systematic review and meta-analysis. PLoS One. 2022;17(11):e0276774. doi: 10.1371/journal.pone.0276774
32. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704. doi: 10.1056/NEJMoa2021436
33. Zhang H, Li X, Huang L, Gu X, Wang Y, Liu M, et al. Lung-function trajectories in COVID-19 survivors after discharge: a two-year longitudinal cohort study. EClinicalMedicine. 2022;54:101668. doi: 10.1016/j.eclinm.2022.101668
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
